Methods for decreasing detrusor muscle overactivity

• US 20050239890A1
• Filed: 05/10/2005
• Published: 10/27/2005
• Est. Priority Date: 03/21/2003
• Status: Abandoned Application

• Current Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Original Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Inventors: Thor, Karl Bruce, Landau, Steven B., Brettman, Lee R., Fraser, Matthew Oliver, Ricca, Daniel J., Burgard, Edward C.
• Application Number:
  US11/126,062
• Publication Number:
  US 20050239890A1
• Time in Patent Office: Days
• US Class Current: 514/561
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/12 Antidiuretics, e.g. drugs for diabetes insipidus ADH A61P5/10

Abstract

A method is provided for using α₂δ subunit calcium channel modulators or other compounds that interact with the α₂δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α₂δ subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Claims

1-19. -19. (canceled)

20. A method for decreasing overactivity of the detrusor muscle, comprising administering to an individual in need thereof a therapeutically effective amount of an α

₂δ

subunit calcium channel modulator and an antimuscarinic.

21. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator and said antimuscarinic are contained within a single pharmaceutical formulation.

22. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator and said antimuscarinic are contained within separate pharmaceutical formulations.

23. The method of claim 22, wherein said α

₂δ

subunit calcium channel modulator and said antimuscarinic are administered concurrently.

24. The method of claim 22, wherein said α

₂δ

subunit calcium channel modulator and said antimuscarinic are administered sequentially.

25. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator and said antimuscarinic are administered on an as-needed basis.

26. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator and said antimuscarinic are administered prior to commencement of an activity wherein decreasing overactivity of the detrusor muscle would be desirable.

27. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator and said antimuscarinic are administered orally, transmucosally, sublingually, buccally, intranasally, transurethrally, rectally, by inhalation, topically, transdermally, parenterally, intrathecally, vaginally, or perivaginally.

28. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is a GABA analog.

29. The method of claim 28, wherein said GABA analog is Gabapentin or Pregabalin.

30. The method of claim 20, wherein said antimuscarinic is Oxybutynin, Tolterodine, Propiverine, or Solifenacin monohydrochloride.

31. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Oxybutynin.

32. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Tolterodine.

33. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Propiverine.

34. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is Gabapentin and wherein said antimuscarinic is Solifenacin monohydrochloride.

35. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Oxybutynin.

36. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Tolterodine.

37. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Propiverine.

38. The method of claim 20, wherein said α

₂δ

subunit calcium channel modulator is Pregabalin and wherein said antimuscarinic is Solifenacin monohydrochloride.

39. A method for decreasing detrusor instability, comprising administering to an individual in need thereof a therapeutically effective amount of an α

₂δ

subunit calcium channel modulator and an antimuscarinic.